<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0010">
 <label>Table 2</label>
 <caption>
  <p>Summary of the potential repurposed drugs currently in clinical trials for treatment of COVID-19.</p>
 </caption>
 <alt-text id="al0030">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center">Sr. no</th>
    <th align="center">Potential drug candidate</th>
    <th align="center">Mechanism of action/rationale</th>
    <th align="center">Current clinical status</th>
    <th align="center">On-going Clinical Trial for COVID-19 in different countries</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="5" align="center">Anti-viral drugs</td>
   </tr>
   <tr>
    <td>1.</td>
    <td>Baloxavir</td>
    <td>Antiviral active against influenza viruses</td>
    <td>FDA approved anti-viral medication for treatment of influenza A and influenza B flu in Japan and in the United States</td>
    <td align="center">Chinese Clinical Trial Registry:
     <break/>(CHiCTR2000029544), (CHiCTR2000029548)
    </td>
   </tr>
   <tr>
    <td>2.</td>
    <td>Favipiravir</td>
    <td>Broad-spectrum antiviral drug which cause inhibition of viral RNA-dependent RNA polymerase against various viruses, including coronaviruses</td>
    <td>Favipiravir is approved for treatment of influenza in Japan</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336904" id="ir0035" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336904</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04349241" id="ir0040" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04349241</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336904" id="ir0045" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336904</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04346628" id="ir0050" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04346628</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04310228" id="ir0055" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04310228</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04319900" id="ir0060" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04319900</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04303299" id="ir0065" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04303299</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333589" id="ir0070" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333589</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336904" id="ir0075" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336904</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04345419" id="ir0080" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04345419</ext-link>) (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04351295" id="ir0085" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04351295</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04349241" id="ir0090" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04349241</ext-link>)
     <break/>
     <break/>Chinese Clinical Trial Registration Number:
     <break/>(ChiCTR2000029544), (ChiCTR2000030113) (ChiCTR2000029548), (ChiCTR2000030894) (ChiCTR2000030987)
     <break/>
     <break/>Japan Clinical Trial Registration Number:
     <break/>(JapicCTI-205,238), (JPRN-jRCTs031190226),
     <break/>(JPRN-jRCTs041190120)
    </td>
   </tr>
   <tr>
    <td>3.</td>
    <td>Lopinavir
     <break/>Ritonavir
    </td>
    <td>In-vitro activity against SARS-CoV-2 in Vero E6 cells; In-vitro activity against SARS-CoV-1 and MERS-CoV; showed protection in animal studies for treatment of MERS-CoV</td>
    <td>Lopinavir/Ritonavir is an FDA approved antiretroviral drug of the protease inhibitor class used to treat HIV infection</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04307693" id="ir0095" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04307693</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276688" id="ir0100" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04276688</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04328012" id="ir0105" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328012</ext-link>)
    </td>
   </tr>
   <tr>
    <td>4.</td>
    <td>Oseltamivir</td>
    <td>Anti-viral active against influenza viruses</td>
    <td>Oseltamivir is an FDA approved drug used to treat and prevent influenza A and influenza B</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04303299" id="ir0110" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04303299</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04261270" id="ir0115" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04261270</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04255017" id="ir0120" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04255017</ext-link>)
    </td>
   </tr>
   <tr>
    <td>5.</td>
    <td>Remdesivir
     <break/>(recently approved by FDA as Orphan drug for COVID-19)
    </td>
    <td>Broad-spectrum anti-viral (including coronaviruses)</td>
    <td>Remdesivir is an antiviral drug, act as nucleotide analog, specifically an adenosine analogue, which inserts into viral RNA chains, causing their premature termination.</td>
    <td align="center">National Clinical Trial Identifier: (Phase III)
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04292899" id="ir0125" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04292899</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04292730" id="ir0130" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04292730</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04280705" id="ir0135" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04280705</ext-link>)
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04323761" id="ir0140" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04323761</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04302766" id="ir0145" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04302766</ext-link>)
    </td>
   </tr>
   <tr>
    <td>6.</td>
    <td>Umifenovir</td>
    <td>Broad-spectrum anti-viral with in-vitro activity against various viruses, including coronaviruses</td>
    <td>Umifenovir is an antiviral treatment used for influenza infection used in Russia and China.</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04252885" id="ir0150" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04252885</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04260594" id="ir0155" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04260594</ext-link>)
     <break/>
     <break/>Chinese Clinical Trial Registration Number:
     <break/>(ChiCTR200030254)
    </td>
   </tr>
   <tr>
    <td colspan="5">  </td>
   </tr>
   <tr>
    <td colspan="5" align="center">Supporting agents</td>
   </tr>
   <tr>
    <td>7.</td>
    <td>Anakinra</td>
    <td>Disease modifying Anti -rheumatic Drug
     <break/>
     <break/>Recombinant human interleukin-1 (IL-1) receptor antagonist; inhibit cytokine release syndrome (CRS) symptoms or cytokine storm in severely ill patients
    </td>
    <td>Anakinra is clinically approved to manage symptoms of rheumatoid arthritis</td>
    <td align="center">
     <break/>National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324021" id="ir0160" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324021</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04356366" id="ir0165" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04356366</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04339712" id="ir0170" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04339712</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04330638" id="ir0175" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04330638</ext-link>)
    </td>
   </tr>
   <tr>
    <td>8.</td>
    <td>Ascorbic acid</td>
    <td>Antioxidant and cofactor for numerous physiologic reactions; may support host defenses against infection and protect host cells against infection induced oxidative stress</td>
    <td>
     <bold>Ascorbic acid</bold> is clinically used to prevent and treat scurvy, a disease caused by a lack of vitamin C
    </td>
    <td align="center">
     <break/>National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04264533" id="ir0180" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04264533</ext-link>)
    </td>
   </tr>
   <tr>
    <td>9.</td>
    <td>Combination of Azithromycin and Hydroxychloroquine</td>
    <td>
     <bold>Azithromycin:</bold> Antibacterial with some in-vitro activity against some viruses (e.g., influenza A H1N1, Zika), has immunomodulatory and anti-inflammatory effects, including effects on proinflammatory cytokines
     <break/>
     <break/>
     <bold>Hydroxychloroquine</bold>: In-vitro activity against various viruses, including coronaviruses, has immunomodulatory activity that theoretically could contribute to an antiinflammatory response in patients with viral infections
    </td>
    <td>Azithromycin is clinically used as adjunctive therapy to management of certain respiratory conditions (e.g., bronchiectasis, bronchiolitis, cystic fibrosis, COPD exacerbations, ARDS)
     <break/>
     <break/>Hydroxychloroquine is also FDA-approved to treat malaria and autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis
    </td>
    <td align="center">
     <break/>
     <break/>National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04329832" id="ir0185" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04329832</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04339426" id="ir0190" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04339426</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334382" id="ir0195" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04334382</ext-link>),
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336332" id="ir0200" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336332</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04341870" id="ir0205" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04341870</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04332094" id="ir0210" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04332094</ext-link>),
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04335552" id="ir0215" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04335552</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04344379" id="ir0220" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04344379</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04344444" id="ir0225" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04344444</ext-link>),
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04345861" id="ir0230" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04345861</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04321278" id="ir0235" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04321278</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04322396" id="ir0240" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04322396</ext-link>),
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04322123" id="ir0245" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04322123</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04354428" id="ir0250" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04354428</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04341727" id="ir0255" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04341727</ext-link>),
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04355052" id="ir0260" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04355052</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324463" id="ir0265" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324463</ext-link>)
    </td>
   </tr>
   <tr>
    <td>10.</td>
    <td>Colchicine</td>
    <td>Exerts broad antiinflammatory and immunomodulatory effects through multiple mechanisms, may combat the hyperinflammatory state of COVID-19 (e.g., cytokine storm) by suppressing proinflammatory cytokines and chemokines</td>
    <td>
     <bold>Colchicine</bold> is clinically approved medication used to treat gout and Behçet's disease
    </td>
    <td align="center">National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04326790" id="ir0270" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04326790</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04322565" id="ir0275" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04322565</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04328480" id="ir0280" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328480</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04350320" id="ir0285" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04350320</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04355143" id="ir0290" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04355143</ext-link>)
    </td>
   </tr>
   <tr>
    <td>11.</td>
    <td>Corticosteroids</td>
    <td>Potent anti-inflammatory and antifibrotic properties; use of corticosteroids may prevent an extended cytokine response and may accelerate resolution of pulmonary and systemic inflammation in pneumonia, may combat cytokine storm</td>
    <td>Corticosteroid drugs are clinically used to treat rheumatoid arthritis, lupus, asthma, allergies and many other inflammatory conditions</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04327401" id="ir0295" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04327401</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04344730" id="ir0300" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04344730</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04348305" id="ir0305" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04348305</ext-link>)
    </td>
   </tr>
   <tr>
    <td>12.</td>
    <td>Nitric oxide</td>
    <td>Selective pulmonary vasodilator; may be useful in the adjunctive treatment of acute respiratory distress syndrome (ARDS), a potential complication of COVID-19</td>
    <td/>
    <td align="center">National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04306393" id="ir0310" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04306393</ext-link>)
    </td>
   </tr>
   <tr>
    <td>13.</td>
    <td>Ruxolitinib</td>
    <td>Janus kinase (JAK) 1 and 2 inhibitor; 7 may potentially combat cytokine release syndrome (CRS) in severely ill patients
     <break/>
     <break/>Ability to inhibit a variety of proinflammatory cytokines, including interferon, during viral infections such as COVID-19
    </td>
    <td>Ruxolitinib is a clinically approved Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04331665" id="ir0315" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04331665</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334044" id="ir0320" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04334044</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04338958" id="ir0325" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338958</ext-link>)
     <break/>
     <break/>Chinese Clinical Trial Registry
     <break/>(ChiCTR2000029580), (ChiCTR2000030170)
    </td>
   </tr>
   <tr>
    <td>14.</td>
    <td>Sarilumab</td>
    <td>Recombinant humanized monoclonal antibody specific for the interleukin-6 (IL-6) receptor; may potentially combat cytokine release syndrome (CRS) and pulmonary symptoms in severely ill patients</td>
    <td>Sarilumab is an FDA approved human monoclonal antibody against the interleukin-6 receptor used for the treatment of rheumatoid arthritis.</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04357808" id="ir0330" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04357808</ext-link>), (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04315298" id="ir0335" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04315298</ext-link>)
    </td>
   </tr>
   <tr>
    <td>15.</td>
    <td>Sirolimus</td>
    <td>Immunosuppressive agent (mTOR inhibitor)
     <break/>mTOR complex 1 (mTORC1) is involved in the replication of various viruses, including coronavirus
    </td>
    <td>Sirolimus, also known as rapamycin, clinically used to coat coronary stents, prevent organ transplant rejection.</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04341675" id="ir0340" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04341675</ext-link>)
    </td>
   </tr>
   <tr>
    <td>16.</td>
    <td>ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)</td>
    <td>
     <bold>
      <italic>Hypothetical benefit:</italic>
     </bold> ACE inhibitors or ARBs may have a protective effect against lung damage or may have paradoxical effect in terms of virus binding
     <break/>
     <break/>
     <break/>
     <bold>
      <italic>Hypothetical harm:</italic>
     </bold> Human pathogenic coronaviruses bind to their target cells through angiotensin converting enzyme 2 (ACE2)0.1, 4, 5 Expression of ACE2 may be increased in patients treated with ACE inhibitors or ARBs.1, 4, 8 Increased expression of ACE2 may potentially facilitate COVID-19 infections.1
    </td>
    <td>Renin Angiotensin Aldosterone System Inhibitor, clinically approved for treatment of hypertension.</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04312009" id="ir0345" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04312009</ext-link>)
    </td>
   </tr>
   <tr>
    <td>17.</td>
    <td>Anticoagulants (low molecular weight heparin [LMWH], unfractionated heparin [UFH])</td>
    <td>Current evidence indicates that patients with severe COVID-19 may develop a hypercoagulable state.
     <break/>
     <break/>Coagulation abnormalities observed in these patients include thrombotic disseminated intravascular coagulation (DIC), venous thromboembolism, elevated D-dimer levels, high fibrinogen levels, and microvascular thrombosis in the pulmonary vasculature
    </td>
    <td>Heparin is clinically approved anti-coagulant.</td>
    <td align="center">National Clinical Trial Identifier:
     <break/>(
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04345848" id="ir0350" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04345848</ext-link>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
